用于治疗外周动脉疾病的proniosomes纳米粒子
Preyash A Panchal1, Shruti Patel1, Asha Patel1
1Department of Pharmaceutics, Parul Institute of Pharmacy, Parul University, Vadodara, Gujarat, 391760, India.
Pharmaceutical nanotechnology
|September 13, 2023
概括
普罗尼奥索姆为治疗外围动脉疾病 (PAD) 提供了一个稳定,有效的前血管系统. 这些纳米粒子克服了尼奥体的局限性,为血管缩和PAD管理提供了有前途的治疗方法.
科学领域:
- 制药纳米技术 制药纳米技术
- 药物输送系统 药物输送系统
- 血管医学 血管医学
背景情况:
- 周围动脉疾病 (PAD) 涉及动脉样硬化斑块的积累,导致下肢动脉堵塞和血管结等症状.
- PAD显著增加了从并发冠状动脉和脑血管动脉样硬化的死亡风险.
研究的目的:
- 通过开发proniosomes作为一个先进的前状载体系统来解决体 (融合,聚合,泄漏) 的局限性.
- 探索proniosome纳米颗粒在治疗外围动脉疾病中的有效性.
主要方法:
- 使用有机溶剂,表面活性剂,胆固醇和水化介质制备的proniosome配方.
- 在proniosome纳米粒子合成中使用的同化相位分离技术.
- 盒式设计用于优化配方批量.
主要成果:
- 普罗尼索姆纳米粒子在治疗外围动脉疾病方面表现出有利的特性和有效性.
- 这项研究强调了proniosomes作为一种可行的PAD治疗的前血管系统.
结论:
- 前基因组提供了增强的药物稳定性和输送,克服了与基因组相关的问题.
- 不同的制备技术可以影响proniosome的发育和药物特征.
- 与传统的囊泡相比,proniosomes具有有利的处理,储存和制造特性.
相关概念视频
Peripheral Artery Disease III: Interprofessional Care
11
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
11
Peripheral Artery Disease IV: Nursing Management
12
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
12
Peripheral Artery Disease I: Introduction
9
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs but also impacts other areas, such as the arms, thereby impairing overall circulation and organ function.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty deposits inside the arterial...
9
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
210
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
210
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
183
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
183
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
15
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
15


